Drug
Ixo Vec
Ixo Vec: highest development phase Phase 3, developed by Adverum Biotechnologies. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Adverum Biotechnologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ixo-vec NCT07482176 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) |
| Ixo-vec NCT06856577 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) |
| Ixo-vec NCT07630649 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD |
Latest
No recent events.
Follow Ixo Vec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.